Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.
Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148
Inhaled aerosol viral-vectored vaccines against tuberculosis.
Stylianou E. and Satti I., (2024), Current opinion in virology, 66
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.
Wajja A. et al, (2024), The Lancet. Infectious diseases, 24, 285 - 296
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
Wajja A. et al, (2024), The Lancet Infectious Diseases, 24, e78 - e79
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M. et al, (2020), Vaccine, 38, 779 - 789
Cytomegalovirus infection is a risk factor for tuberculosis disease in infants.
Müller J. et al, (2019), JCI insight, 4
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16
Current approaches toward identifying a correlate of immune protection from tuberculosis
Satti I. and McShane H., (2019), Expert Review of Vaccines, 18, 43 - 59
Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
O’Shea MK. et al, (2018), Scientific Reports, 8
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
Wajja A. et al, (2018), Wellcome Open Research, 3, 121 - 121
Human Immunodeficiency Virus Infection Impairs Th1 and Th17 Mycobacterium tuberculosis–Specific T-Cell Responses
Murray LW. et al, (2018), The Journal of Infectious Diseases, 217, 1782 - 1792
Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines
Harris SA. et al, (2018), Tuberculosis, 108, 99 - 105
Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials
Smith SG. et al, (2017), PLOS ONE, 12, e0184391 - e0184391
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
Wajja A. et al, (2017), PLOS Neglected Tropical Diseases, 11, e0005440 - e0005440
TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development
Kaufmann SHE. et al, (2017), Frontiers in Immunology, 8
Correction: Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants
Fletcher HA. et al, (2016), Nature Communications, 7
T-cell activation is an immune correlate of risk in BCG vaccinated infants
Fletcher HA. et al, (2016), Nature Communications, 7
A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
Minhinnick A. et al, (2016), Vaccine, 34, 1412 - 1421
Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity
Minhinnick A. et al, (2016), Journal of Infectious Diseases, 213, 824 - 830